<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076477</url>
  </required_header>
  <id_info>
    <org_study_id>scch201402</org_study_id>
    <nct_id>NCT02076477</nct_id>
  </id_info>
  <brief_title>The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）</brief_title>
  <acronym>OITROLC</acronym>
  <official_title>The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mianyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage
      iv lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>short-term effects（The response rate，RR）</measure>
    <time_frame>3 months after the end of the treatment</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors (RECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS（progression-free survival）</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI) and lung cancer subscale (LCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>esophagitis and pneumonitis</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Grade 3-5 esophagitis and pneumonitis adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other grade 3-5 adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Other grade 3-5 adverse events as assessed by NCI CTCAE v3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Oligo-metastatic Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.
chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.
chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent chemoradiotherapy</intervention_name>
    <description>Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors〉3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel:60mg/m2 d1,Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>pemetrexed: 500mg/m2 d1,Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin：25mg/m2 d1-3，Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years old , male or female

          -  Pathologically or cytologically proven oligometastatic stage IV NSCLC non-small cell
             lung cancer（NSCLC）

          -  Primary tumors can be measured

          -  Distant organ metastases number ≤ 5

          -  Karnofsky score &gt;70,Zubrod performance status 0-1

          -  Estimated life expectancy of at least 12 weeks

          -  reproductive age women should ensure that before entering the study period
             contraception

          -  Hemoglobin≥10.0g/dL,WBC≥ 4000 cells/mm³,Platelet count≥100,000 cells/mm³

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper
             limit of normal,bilirubin normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Patients have good compliance to treatment and follow-up of acceptance.

        Exclusion Criteria:

          -  Allergic to pemetrexed, cisplatin, docetaxel and contrast medium

          -  Distant metastases organs &gt; 5

          -  The primary tumor or lymph node already received surgical treatment (except for
             biopsy)

          -  Patient who received radiotherapy for primary tumor or lymph node

          -  Patient who received the the epidermal growth factor targeted therapy

          -  Patient who received chemotherapy or immunotherapy

          -  Patient who suffered from other malignant tumor

          -  Patient who have taken other drug test within 1 month

          -  Pregnant woman or Lactating Women and Women in productive age who refuse to take
             contraception in observation period

          -  Subject with a severe allergic history or idiosyncratic

          -  Subject with severe pulmonary and cardiopathic disease history

          -  Refuse or incapable to sign the informed consent form of participating this trial

          -  Drug abuse or alcohol addicted

          -  Subject with a Personality or psychiatric diseases, people with no legal capacity or
             people with limited capacity for civil conduct
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JIAHUA LV, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XIAOHU WANG, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gansu Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XIAOBO DU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mianyang Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BING LU, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Guizhou Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TAO LI, MD, PhD</last_name>
    <phone>86-18908178818</phone>
    <email>litaoxmf@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital &amp; Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAO LI, MD, PhD</last_name>
      <phone>86-18908178818</phone>
      <email>litaoxmf@163.com</email>
    </contact>
    <investigator>
      <last_name>TAO LI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XIAOHU WANG, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>XIAOBO DU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BING LU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>LI TAO</investigator_full_name>
    <investigator_title>Section Head</investigator_title>
  </responsible_party>
  <keyword>intervention time</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>oligometastatic</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

